2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2015
S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
Leichman C, McDonough S, Smalley S, Billingsley K, Lenz H, Beldner M, Hezel A, Velasco M, Guthrie K, Blanke C, Hochster H. S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). Journal Of Clinical Oncology 2015, 33: 3516-3516. DOI: 10.1200/jco.2015.33.15_suppl.3516.Peer-Reviewed Original Research
2008
Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris A, Billingsley K, Hayanga A, Matthews B, Baldwin L, Birkmeyer J. Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal Of The National Cancer Institute 2008, 100: 1740-1740. PMID: 18477800, PMCID: PMC2766763, DOI: 10.1093/jnci/djn396.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantConfidence IntervalsDecision MakingFemaleHealth Services AccessibilityHealthcare DisparitiesHumansLogistic ModelsMaleMedical OncologyMedical Record LinkageMedicareNeoplasm StagingPractice Patterns, Physicians'Radiation OncologyRadiotherapy, AdjuvantRectal NeoplasmsReferral and ConsultationSEER ProgramUnited StatesWhite PeopleConceptsRectal cancerAdjuvant therapyBlack patientsWhite patientsRadiation oncologistsAdjuvant treatmentMedical oncologistsEnd Results-Medicare dataProvider decision makingPatient-provider interactionsFrequency of consultationsLow treatment ratesClinical characteristicsElderly patientsConsultation ratesOncology referralTreatment disparitiesPatient preferencesProvider characteristicsRadiation therapyPatientsOncologistsTherapyStage IITreatment ratesDoes Surgeon Case Volume Influence Nonfatal Adverse Outcomes after Rectal Cancer Resection?
Billingsley K, Morris A, Green P, Dominitz J, Matthews B, Dobie S, Barlow W, Baldwin L. Does Surgeon Case Volume Influence Nonfatal Adverse Outcomes after Rectal Cancer Resection? Journal Of The American College Of Surgeons 2008, 206: 1167-1177. PMID: 18501815, PMCID: PMC3103396, DOI: 10.1016/j.jamcollsurg.2007.12.042.Peer-Reviewed Original ResearchConceptsSurgeon volumeSurgeon ageProcedural interventionEnd Results (SEER) cancer registry programNonfatal adverse outcomesRectal cancer careMajor postoperative complicationsRectal cancer resectionEnd Results (SEER) dataCancer Registry ProgrammeRectal cancer patientsRectal cancer surgeryRetrospective cohort designHigh-volume surgeonsRectal cancer operationsPostoperative complicationsColorectal surgeryHospital volumeSurgical complicationsCancer resectionPrimary outcomeRectal cancerSevere complicationsCancer surgeryCancer operations
2004
Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis
Morris A, Billingsley K, Baxter N, Baldwin L. Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis. JAMA Surgery 2004, 139: 151-155. PMID: 14769572, DOI: 10.1001/archsurg.139.2.151.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBlack PeopleCohort StudiesColectomyConfidence IntervalsCross-Sectional StudiesFemaleHealth Care SurveysHumansIncidenceLogistic ModelsMaleMiddle AgedNeoplasm StagingOdds RatioPostoperative ComplicationsProbabilityRectal NeoplasmsRisk FactorsSEER ProgramSex FactorsSocioeconomic FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsRectal cancer patientsRectal cancerCancer patientsRadiation therapyCross-sectional cohort studyRadiation treatmentRacial disparitiesEnd Results (SEER) databaseSphincter-sparing proceduresRectal cancer treatmentAdvanced disease stagePopulation-based dataDelivery of careSignificant racial disparitiesAdvanced diseaseAggressive screeningCohort studySurgical therapyPelvic cancerSurveillance EpidemiologyResults databaseTreatment disparitiesDisease stageMinority patientsSurgical care